PHERGain and PHERGain-2 advance therapeutic de-escalation in early HER2-positive breast cancer in selected patients

Results from the PHERGain study confirm that the combination of two targeted agents allows one third of patients to be treated without chemotherapy and achieves disease-free survival rates close to 90% five years after surgery. The PHERGain-2 trial, published simultaneously in the...